TABLETING 75
The results Compression Study 5mg Olmesartan Compression study Olmesartan 20mg
Filling Pre-compression Die
filling height (mm)
5,114 5,114 5,113 5,110 5,111
Upper punch compression force (kN)
0.86 0.86 0.87 0.85 0.88
filling height (mm)
7,300 7,299 7,299 7,299 7,298
Upper punch compression force (kN)
0.97 1.01 1.02 1.06 1.09
Main compression
Lower punch compression force (kN)
0.96
0.97 0.98 0.96 0.99
Filling Pre-compression Die
Lower punch compression force (kN)
1.13
1.16 1.18 1.22 1.24
Upper punch compression force (kN)
1.99
3.87 8.53 13.62 16.79
Upper punch compression force (kN)
2.20
2.70 4.50 6.50 8.61
Lower punch compression force (kN)
2.10
4.11 8.94 14.14 17.76
Lower punch compression force (kN)
2.42
2.99 4.97 7.08 9.31
Upper Punch Force (kN)
70.25
136.90 301.57 481.57 593.83
Main compression
Upper Punch Force (kN)
43.78
53.72 89.53 129.39 171.26
Ejection force (kN) 37
47 65 80 78
Weight (mg)
177.1
178.6 178 180 181
Ejection force (kN) 33
50 58 64 70
Weight (mg)
70.9
71.0 69 73 73
Measures
Measured thickness (mm)
3.15
2.99 2.8 2.8 2.8
Measured thickness (mm)
4.15
4.02 3.8 3.7 3.6
Tablet diameter (mm)
6.05
6.00 6.01 6.01 6.01
Measures
Tablet diameter (mm)
7.99
7.99 7.98 8.00 7.99
Hardness (N)
23.3
28.7 49.00 68.67 80.33
Olmesartan 20mg, settings and tablet parameter, mean values
Hardness (N)
18.0
37.0 64.67 74.00 73.33
Olmesartan 5g settings and tablet parameter, mean values
Te tables above provide the setting data for the rotary production press (die filling, pre-compression and main- compression) that will lead to a specific tablet hardness within the permissible specification range for each dosing tablet strength, without the need to establish that data using the production press; a process that would consume large amounts
of product and occupy valuable production time. Based on this data, the user
is now in a position to choose the optimal combination of tablet hardness (high enough) and compression – as well as ejection forces (as low as possible to minimise wear on the machine).
For more information ✔ at
www.scientistlive.com/eurolab www.scientistlive.com
Gerd Hueffmann is with Kilian Tableting.
www.romaco.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84